Furthermore, while current clinical trials of CD100-targeted monoclonal antibodies (e.g., Pepinemab) primarily focus on neurological disorders and cancer, CD100’s potent immunoregulatory properties in viral infections—particularly its capacity to activate immune cells—highlight its untapped potential as a therapeutic target for chronic viral persistence. The gene discussed is SEMA4D; the disease is cancer.